Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veraxa Biotech Holding AG Days Payable Chart
Veraxa Biotech Holding AG Annual Data
Trend
Dec23
Dec24
Dec25
Days Payable
0.00
0.00
41,865.50
Veraxa Biotech Holding AG Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Days Payable
0.00
0.00
0.00
17,684.25
0.00
VRXA vs TTRX, IRD, IFRX: Days Payable Comparison
For the Biotechnology subindustry, Veraxa Biotech Holding AG's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veraxa Biotech Holding AG Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Veraxa Biotech Holding AG's Days Payable distribution charts can be found below:
* The bar in red indicates where Veraxa Biotech Holding AG's Days Payable falls into.
Veraxa Biotech Holding AG Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Veraxa Biotech Holding AG's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veraxa Biotech Holding AG (VRXA) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Veraxa Biotech Holding AG and its competitors. Over the past decade, Veraxa Biotech Holding AG's Days Payable has ranged from 41,865.50 to 44,822.00. According to the industry distribution chart, Veraxa Biotech Holding AG ranks #18 out of 703 companies in the Biotechnology industry, placing it in the top 2.6%.
Is Veraxa Biotech Holding AG's Days Payable too high?
Veraxa Biotech Holding AG's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 41,865.50 to a high of 44,822.00. Based on the distribution chart, Veraxa Biotech Holding AG ranks #18 out of 703 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Veraxa Biotech Holding AG has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Veraxa Biotech Holding AG's Days Payable compare to TTRX and IRD?
According to the Biotechnology industry distribution chart, Veraxa Biotech Holding AG ranks #18 out of 703 companies for Days Payable. This places Veraxa Biotech Holding AG in the top 3% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.84. Historically, Veraxa Biotech Holding AG's own Days Payable has ranged from 41,865.50 to 44,822.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Veraxa Biotech Holding AG and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veraxa Biotech Holding AG's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veraxa Biotech Holding AG stock overvalued right now?
Veraxa Biotech Holding AG (VRXA) has a current Days Payable of 0.00. The current Days Payable is 0.00. Veraxa Biotech Holding AG's overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Veraxa Biotech Holding AG (VRXA), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
6GF Score
Get the complete analysis for VRXA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRXA has been successfully added to your 
